The Role of 18F-Fluciclovine-PET/CT in Improving Cancer Control Compared With Conventional Imaging Alone for Salvage Postprostatectomy Radiotherapy, the EMPIRE-1 Trial Journal Club – Christopher Wallis & Zachary Klaassen

September 10, 2021

Christopher Wallis and Zachary Klaassen discuss a publication entitled, “18F-Fluciclovine-PET/CT Imaging versus Conventional Imaging Alone to Guide Post-Prostatectomy Salvage Radiotherapy for Prostate Cancer, the EMPIRE-1 Study”. This Journal Club kicks off with a discussion about adjuvant radiotherapy in patients with prostate cancer. Dr. Wallis discusses how adjuvant radiotherapy improves biochemical progression-free survival, however, the effects on overall survival are much less clear. About halfway through the conversation, Dr. Klaassen discusses the results of the study. Further, he discusses how the inclusion of 18F-fluciclovine-PET into post-prostatectomy radiotherapy decision-making improved survival. This Journal Club concludes with a discussion about the need for further study on novel PET radiotracers for prostate cancer patients.

Biographies:

Christopher J.D. Wallis, MD, Ph.D., Instructor in Urology, Vanderbilt University Medical Center, Nashville, Tennessee

Zachary Klaassen, MD, MSc, Urologic Oncologist, Assistant Professor Surgery/Urology at the Medical College of Georgia at Augusta University, Georgia Cancer Center


Read the Full Video Transcript

email news signup